Ad is loading...
NKTX
Price
$2.53
Change
-$0.17 (-6.30%)
Updated
Nov 15 closing price
122 days until earnings call
SABS
Price
$3.10
Change
-$0.60 (-16.22%)
Updated
Nov 15 closing price
Ad is loading...

NKTX vs SABS

Header iconNKTX vs SABS Comparison
Open Charts NKTX vs SABSBanner chart's image
Nkarta
Price$2.53
Change-$0.17 (-6.30%)
Volume$1.26M
CapitalizationN/A
SAB Biotherapeutics
Price$3.10
Change-$0.60 (-16.22%)
Volume$84.88K
CapitalizationN/A
NKTX vs SABS Comparison Chart
Loading...
NKTX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SABS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
NKTX vs. SABS commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NKTX is a Sell and SABS is a StrongSell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (NKTX: $2.53 vs. SABS: $3.10)
Brand notoriety: NKTX and SABS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NKTX: 164% vs. SABS: 96%
Market capitalization -- NKTX: $178.54M vs. SABS: $28.61M
NKTX [@Biotechnology] is valued at $178.54M. SABS’s [@Biotechnology] market capitalization is $28.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NKTX’s FA Score shows that 1 FA rating(s) are green whileSABS’s FA Score has 0 green FA rating(s).

  • NKTX’s FA Score: 1 green, 4 red.
  • SABS’s FA Score: 0 green, 5 red.
According to our system of comparison, both NKTX and SABS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NKTX’s TA Score shows that 4 TA indicator(s) are bullish while SABS’s TA Score has 5 bullish TA indicator(s).

  • NKTX’s TA Score: 4 bullish, 4 bearish.
  • SABS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both NKTX and SABS are a good buy in the short-term.

Price Growth

NKTX (@Biotechnology) experienced а -20.69% price change this week, while SABS (@Biotechnology) price change was -11.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

NKTX is expected to report earnings on Mar 20, 2025.

SABS is expected to report earnings on May 09, 2024.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NKTX($179M) has a higher market cap than SABS($28.6M). SABS YTD gains are higher at: -54.909 vs. NKTX (-61.667). SABS has higher annual earnings (EBITDA): -35.03M vs. NKTX (-115.21M). NKTX has more cash in the bank: 325M vs. SABS (37.3M). SABS has less debt than NKTX: SABS (5.34M) vs NKTX (85.6M). NKTX (0) and SABS (0) have equivalent revenues.
NKTXSABSNKTX / SABS
Capitalization179M28.6M626%
EBITDA-115.21M-35.03M329%
Gain YTD-61.667-54.909112%
P/E RatioN/AN/A-
Revenue00-
Total Cash325M37.3M871%
Total Debt85.6M5.34M1,602%
TECHNICAL ANALYSIS
Technical Analysis
NKTXSABS
RSI
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
78%
Momentum
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
71%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 12 days ago
85%
Bullish Trend 13 days ago
67%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 11 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
59%
View a ticker or compare two or three
Ad is loading...
NKTX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SABS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AOMR9.80-0.06
-0.61%
Angel Oak Mortgage REIT
TEX51.98-0.59
-1.12%
Terex Corp
FCUV0.23-0.01
-3.31%
Focus Universal
CCEP75.76-3.01
-3.82%
Coca-Cola Europacific Partners plc
GYRE13.12-0.72
-5.20%
Gyre Therapeutics

NKTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NKTX has been loosely correlated with FATE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTX jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NKTX
1D Price
Change %
NKTX100%
-6.30%
FATE - NKTX
51%
Loosely correlated
-2.88%
PGEN - NKTX
51%
Loosely correlated
-7.11%
ALLO - NKTX
47%
Loosely correlated
-7.72%
BCRX - NKTX
46%
Loosely correlated
-5.64%
CRBU - NKTX
45%
Loosely correlated
-4.78%
More

SABS and

Correlation & Price change

A.I.dvisor tells us that SABS and HOOK have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SABS and HOOK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SABS
1D Price
Change %
SABS100%
-16.22%
HOOK - SABS
30%
Poorly correlated
-4.46%
RLAY - SABS
27%
Poorly correlated
-8.84%
ATNF - SABS
25%
Poorly correlated
-6.72%
NKTX - SABS
25%
Poorly correlated
-6.30%
JAGX - SABS
24%
Poorly correlated
-7.69%
More